Drug-eluting stents articles

El tratamiento endovascular parece superior a la cirugía en aneurismas rotos

Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference

Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference

Patients with infrarenal abdominal aortic aneurysm (AAA) and ≥ 30 mm neck diameter have 3 times higher risk of type 1A endoleak and 5 times higher risk of rupture at follow up after standard endovascular aneurysm repair (EVAR), as well as lower survival rate. This could tilt the scales against EVAR, or at best call

Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy

Optical coherence tomography (OCT)-guided drug-eluting stent implantation improves early strut coverage compared with angiography-guided angioplasty. No difference was observed in terms of strut coverage between permanent-polymer everolimus-eluting stents and bioresorbable-polymer biolimus-eluting stents. Short-term dual antiplatelet therapy may be feasible in selected patients with early strut coverage.   This study sought to measure early strut coverage

AHA 2018 | DES de última generación similares a los de 2° generación más allá del polímero

AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer

Sirolimus-eluting stents with biodegradable polymer did not offer better outcomes compared with instant-classic (and undoubtedly valid) everolimus-eluting stents with durable polymer such as Xience. New-generation drug-eluting stents (DES) offer better outcomes than first-generation devices after a 10-year follow-up, according to the ISAR-TEST 4 trial presented at the American Heart Association (AHA) Congress Scientific Sessions and published

TCT 2018 | ABSORB IV: todavía le quedan vidas a las plataformas bioabsorbibles

TCT 2018 | ABSORB IV: Much Life Left for Bioresorbable Scaffolds

Previous studies have documented higher rates of adverse events with bioresorbable scaffolds (ABSORB) compared with metallic drug-eluting stents (DES). However, these studies included lesions smaller than recommended for these scaffolds and a suboptimal implantation technique. The ABSORB IV study, presented by Dr. Stone at TCT 2018 and published simultaneously in The Lancet, randomized patients to polymeric everolimus-eluting scaffold Absorb

TCT 2018 | ReCre8 trial: Zotarolimus y polímero permanente vs Amphilimus libre de polímero

TCT 2018 | ReCre8 Trial: Permanent Polymer and Zotarolimus vs. Polymer-Free Amphilimus

Polymer-free amphilimus-eluting stents are a novel technology combining sirolimus and long-chained fatty acids. This enhances the uptake of antiproliferative agents and may be associated with lower restenosis, particularly among patients with diabetes. The new device includes abluminal reservoirs filled with the drug; in consequence, there is no need for polymer. This work compares this new

BIONYX: DES de polímero permanente vs DES ultrafino y polímero bioabsorbible

TCT 2018 | BIONYX: Durable Polymer-Coated vs. Ultrathin-Strut, Bioresorbable Polymer-Coated DES

This work, presented at TCT 2018 and published simultaneously in The Lancet, is the first randomized study comparing a zotarolimus-eluting stent with a new thin-strut structure and limited radiographic visibility (Onyx), and a bioresorbable polymer-coated sirolimus-eluting stent (Orsiro). Onyx was developed to improve visibility while reducing strut thickness. To that end, a dense platinum–iridium core and

TCT 2018 | RESET: DES liberadores de everolimus vs sirolimus de primera generación a largo plazo

TCT 2018 | RESET: Everolimus DES vs. Sirolimus First Generation DES at Long Term

This study had published thrombosis and revascularization rates at one year after stenting, but today one year seems rather short, which is why this cohort was followed up for 5 to 7 years more, to be able to properly assess the differences between first and second generation DES. There were no significant differences a t

TCT 2018 | TALENT: struts ultrafinos y polímero bioabsorbible al menor costo posible

TCT 2018 | TALENT: Ultrathin Struts and Bioresorbable Polymer at the Lowest Possible Cost

This study assessed the Ultra-thin Strut Bioresorbable Polymer-based Coronary DES (Supraflex) against the Xience, with special emphasis in the cost-benefit ratio.   It included a population of 1435 all-comers from 23 centers in 7 European countries, randomized 1:1 (720 Supraflex and 715 Xience). Primary end point was a composite of cardiac death, target vessel myocardial

TCT 2018 | SORT OUT IX: Stent libre de polímero y struts ultrafinos vs polímero bio absorbible

TCT 2018 | SORT OUT IX: Polymer-Free DES with Ultra-Thin Struts vs. Bioresorbable Polymer- Based DES

Polymer persistence in 1st and 2nd generation DES meant to allow drug release has been associated with a chronic inflammatory response that might be associated to restenosis, neo atherosclerosis and stent thrombosis. This is the rationale behind the development of polymer free and bioresorbable polymer-based DES. They have both been compared against permanent polymer DES,

TCT 2018 | LEADERS FREE II: DES sin polímero en alto riesgo de sangrado con 1 mes de antiagregación

TCT 2018 | LEADERS FREE II: Polymer-Free DES in Patients at High Risk for Bleeding with 1 Month of Antiplatelet Therapy

This study was aimed at gaining device registration from the US Food and Drug Administration (FDA) for a polymer-free biolimus A9 drug-coated stent (BioFreedom, Biosensors). The study had two purposes: on the one hand, it meant to reproduce the results of the LEADERS FREE trial (published in 2015) in terms of safety and efficacy with

angioplastia_compleja_octogenario

OCT Provides Hints About the Physiopathology Behind Very Late Stent Thrombosis

Neoatherosclerosis was frequently observed in patients who experienced very late stent thrombosis, particularly those with drug-eluting stents. In-stent plaque rupture was the most common cause of thrombosis and it usually occurred in cases in which the original procedure had been carried out while the patient was undergoing an acute myocardial infarction. Macrophage infiltration can be

Top